Peer-Reviewed Journal Details
Mandatory Fields
Moloney, TC,Hyland, R,O'Toole, D,Paucard, A,Kirik, D,O'Doherty, A,Gorman, AM,Dowd, E
2014
January
Cns Neuroscience & Therapeutics
Heat Shock Protein 70 Reduces alpha-Synuclein-Induced Predegenerative Neuronal Dystrophy in the alpha-Synuclein Viral Gene Transfer Rat Model of Parkinson's Disease
Published
()
Optional Fields
Genetic therapy Heat-shock proteins Parkinson's disease HEAT-SHOCK PROTEINS AXONAL-TRANSPORT DEFECTS MESENCHYMAL STEM-CELLS NEURODEGENERATIVE DISEASES NIGROSTRIATAL SYSTEM MOUSE MODEL HUNTINGTONS-DISEASE INHIBITS APOPTOSIS APAF-1 APOPTOSOME FIBRIL FORMATION
20
50
58
AimsIt has become increasingly evident that the nigrostriatal degeneration associated with Parkinson's disease initiates at the level of the axonal terminals in the putamen, and this nigrostriatal terminal dystrophy is either caused or exacerbated by the presence of -synuclein immunopositive neuronal inclusions. Therefore, strategies aimed at reducing -synuclein-induced early neuronal dystrophy may slow or halt the progression to overt nigrostriatal neurodegeneration. Thus, this study sought to determine if adeno-associated virus (AAV) mediated overexpression of two molecular chaperone heat shock proteins, namely Hsp27 or Hsp70, in the AAV--synuclein viral gene transfer rat model of Parkinson's disease could prevent -synuclein-induced early neuronal pathology.MethodsMale Sprague-Dawley rats were intranigrally coinjected with pathogenic (AAV--synuclein) and putative therapeutic (AAV-Hsp27 or AAV-Hsp70) viral vectors and were sacrificed 18weeks postviral injection.ResultsIntranigral injection of AAV--synuclein resulted in significant -synuclein accumulation in the substantia nigra and striatal terminals which led to significant dystrophy of nigrostriatal dopaminergic neurons without overt nigrostriatal neurodegeneration. Coinjection of AAV-Hsp70, but not AAV-Hsp27, significantly reduced AAV--synuclein-induced neuronal dystrophy.ConclusionsThese data confirm that overexpression of Hsp70 holds significant potential as a disease-modulating therapeutic approach for Parkinson's disease, with protective effects against early-onset -synuclein-induced pathology demonstrated in the AAV--synuclein model.
DOI 10.1111/cns.12200
Grant Details
Publication Themes